COPD with acute moderate to severe exacerbation (according to GOLD guideline 2022) COPD, chronic obstructive pulmonary exacerbation, exacerbation
Conditions
Interventions
Budesonide Metered-Dose inhaler (MDI) 3 puff every 6 hours for 5 days,Dexamethasone 10-20 mg/day or
Prednisolone 30-40 mg/day for 5 days
Experimental Drug,Active Comparator Drug
Budesonide,Standard
Sponsors
Department of Emergency Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age at least 18 years old Diagnosed with COPD by spirometry or clinical symptoms according to GOLD guideline 2022 Presents to emergency department with acute moderate to severe exacerbation according to GOLD guideline 2022 Improves after initial treatment with bronchodilator and 1 dose of intravenous dexamethasone Eligible for Metered-Dose Inhaler used
Exclusion criteria
Exclusion criteria: Acute respiratory failure Hypotension despite sufficient of intravenous fluid and vasopressor Pneumothorax Cardiac arrest Tracheostomy History of systemic corticosteroid used within 1 month prior Long-term oxygen therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment failure 30 days Revisit, worsening symptom, respiratory failure | — |
Secondary
| Measure | Time frame |
|---|---|
| Admission rate 7 days Percent,Intubation rate 7 days Percent,COPD assessment test (CAT) score At arrival Mean or median,COPD assessment test (CAT) score 7 days Mean or median | — |
Countries
Thailand
Contacts
Public ContactUsapan Surabenjawong
Sirairaj Hospital Faculty of Medicine
Outcome results
None listed